

8547. Sipuleucel-T. APC-8015; Provenge. Autologous dendritic cell product loaded *ex vivo* with the recombinant fusion protein **PA2024** consisting of human granulocyte macrophage-colony stimulating factor (GM-CSF) linked to human prostatic acid phosphatase (PAP). Therapeutic vaccine designed to stimulate immunity against PAP expressed on prostate cancer cells. Prepn of target antigen: R. Laus *et al.*, **WO 9724438**; *idem*, **US 5976546** (1997, 1999 both to Dendreon); of antigen presenting cells and pharmacology: E. J. Small *et al.*, *J. Clin. Oncol.* **18**, 3894 (2000). Clinical evaluation in androgen-independent prostate cancer: P. A. Burch *et al.*, *Prostate* **60**, 197 (2004); P. F. Schellhammer, R. M. Hershberg, *World J. Urol.* **23**, 47 (2005). Review of development and therapeutic potential: F. H. Valone *et al.*, *Cancer J.* **7**, Suppl. 2, S53-S61 (2001); B. I. Rini, *Curr. Opin. Mol. Ther.* **4**, 76-79 (2002).

 THERAP CAT: Antineoplastic, immunomodulator.